/Companies

Kivu Bioscience

26 employees on LinkedIn · 7 known investors

Find your way into Kivu Bioscience

Sign up to see every warm intro you have to Kivu Bioscience

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Kivu Bioscience team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

Founders & leadership

MTMohit Trikha
Mohit TrikhaCEO
SRSophia Randolph
Sophia RandolphChief Medical OfficerShe is a medical oncologist with two decades of pharmaceutical and biotech experience, having overseen clinical development strategies for multiple oncology programs across hematologic and solid tumors from early-stage through regulatory approval.

Investors · 7

Funding

SEC filings, press & company announcements

$92M disclosed across 1 round · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Kivu Bioscience do?
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
Who are Kivu Bioscience's investors?
Kivu Bioscience's investors include BioGeneration Ventures, BOM, Gimv, HealthCap, M Ventures, Red Tree Venture, Novo Holdings.
How much funding has Kivu Bioscience raised?
Kivu Bioscience has disclosed $92M raised across 1 round.